STUDY OF EFFECT OF SAROGLITAZAR IN PREDIABETICES WITH DYSLIPIDAEMIA

Abstract

Background: The aim is to assess effect of Saroglitazar in patients with diabetic
dyslipidemia. Subjects and Methods: Eighty- six type II DM patients of either
gender were enrolled and parameters such as serum creatinine, S.G.O.T, S.G.P.T and
lipid profile were determined. Patients were prescribed 4 mg Saroglitazar once daily
and patients were recalled regularly. All variables were recorded at baseline, 12
weeks and 36 weeks. Results: Out of 86 patients, males were 56 and females were
30. The mean weight was 64.2± 3.7Kgs, height was 171.2± 14.2 cms and BMI was
26.2± 5.9 Kg/m2
. The mean total cholesterol level at baseline, 12 weeks and 36 weeks
found to be 324.5, 232.6 and 168.4, triglyceride level was 542.3, 342.5 and 290.5,
LDL-C was 167.3, 114.2 and 105.2, HDL-C was 41.2, 43.2 and 43.6, SGPT was
34.6, 38.2 and 37.2, SGOT 45.3, 42.6 and 40.3 and creatinine level was 0.6, 0.6
and 0.5 respectively. The difference was significant (P< 0.05).
Conclusion:Saroglitazar found to be efficient in diabetic dyslipidemia with very high
triglycerides level.